---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021717"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:35:59.315252+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Esperion files Hatch-Waxman patent suit against Micro Labs over generic NEXLETOL

## Summary
- Filed May 8, 2024 in District of New Jersey against Micro Labs USA Inc. for NEXLETOL generic ANDA.
- Nine ANDA filers sent Paragraph IV certifications; lawsuit triggered 30-month FDA approval stay.
- Esperion intends to file similar suits against remaining eight ANDA filers for NEXLETOL and NEXLIZET.
- Complaint seeks injunction barring FDA approval and permanent injunction until patent expiration.
- Litigation covers Orange-listed patents; company vows to vigorously defend IP.

## SEC filing metadata
- accession: 0001628280-24-021717
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024021717/0001628280-24-021717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024021717/espr-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021717
- JSON: https://secwatch.observer/filing/0001628280-24-021717.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.